aminopropionitrile has been researched along with Disease Exacerbation in 16 studies
Aminopropionitrile: Reagent used as an intermediate in the manufacture of beta-alanine and pantothenic acid.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Given the controversy regarding the appropriate dose of β-aminopropionitrile for induction of aortic dissection models in rats, the purpose of this study was to explore the most suitable concentration of β-aminopropionitrile to establish a high-incidence and low-mortality aortic dissection model." | 8.02 | Establishment and effect evaluation of an aortic dissection model induced by different doses of β-aminopropionitrile in rats. ( Chen, L; Chen, X; Hou, Y; Hu, Y; Lin, Y; Lv, X, 2021) |
| "This study compared three β-aminopropionitrile (BAPN) treatment rats to find the optimal BAPN model for thoracic aortic dissection and aneurysm in one study." | 7.79 | Comparison of β-aminopropionitrile-induced aortic dissection model in rats by different administration and dosage. ( Jing, ZP; Li, HY; Li, JS; Wang, L; Zhang, L, 2013) |
| "Given the controversy regarding the appropriate dose of β-aminopropionitrile for induction of aortic dissection models in rats, the purpose of this study was to explore the most suitable concentration of β-aminopropionitrile to establish a high-incidence and low-mortality aortic dissection model." | 4.02 | Establishment and effect evaluation of an aortic dissection model induced by different doses of β-aminopropionitrile in rats. ( Chen, L; Chen, X; Hou, Y; Hu, Y; Lin, Y; Lv, X, 2021) |
| "This study compared three β-aminopropionitrile (BAPN) treatment rats to find the optimal BAPN model for thoracic aortic dissection and aneurysm in one study." | 3.79 | Comparison of β-aminopropionitrile-induced aortic dissection model in rats by different administration and dosage. ( Jing, ZP; Li, HY; Li, JS; Wang, L; Zhang, L, 2013) |
| "To test the hypothesis that a primary disturbance in lysyl oxidase-like 1 (LOXL1) and elastin metabolism in the lamina cribrosa of eyes with pseudoexfoliation syndrome constitutes an independent risk factor for glaucoma development and progression." | 3.78 | LOXL1 deficiency in the lamina cribrosa as candidate susceptibility factor for a pseudoexfoliation-specific risk of glaucoma. ( Hammer, CM; Hofmann-Rummelt, C; Kruse, FE; Krysta, AW; Pasutto, F; Sasaki, T; Schlötzer-Schrehardt, U; Zenkel, M, 2012) |
| "The hallmarks of aortic dissection comprise aortic inflammatory cell infiltration and elastic fiber disruption, highlighting the involvement of macrophage." | 1.51 | Macrophage metabolic reprogramming aggravates aortic dissection through the HIF1α-ADAM17 pathway ( Jiang, C; Kong, W; Li, X; Lian, G; Liu, H; Pang, Y; Sun, L; Wang, X; Zhang, L; Zhang, T; Zhang, X; Zhang, Y, 2019) |
| "β-Aminopropionitrile (BAPN) is a compound known to cause aortic aneurysms by inhibiting lysyl oxidase, a collagen cross-linking enzyme." | 1.51 | A novel swine model of abdominal aortic aneurysm. ( Ailawadi, G; Cullen, JM; Fashandi, AZ; Johnston, WF; Lu, G; Montgomery, WG; Salmon, M; Shannon, AH; Sharma, A; Spinosa, MD; Su, G; Upchurch, GR, 2019) |
| " We studied the functional contribution of lysyl oxidase (LOX) to collagen stabilization and hepatic fibrosis progression/reversalin vivousing chronic administration of irreversible LOX inhibitor β-aminopropionitrile (BAPN, or vehicle as control) in C57Bl/6J mice with carbon tetrachloride (CCl4)-induced fibrosis." | 1.43 | Lysyl oxidase activity contributes to collagen stabilization during liver fibrosis progression and limits spontaneous fibrosis reversal in mice. ( Greenstein, A; Ikenaga, N; Liu, SB; Peng, ZW; Popov, Y; Schuppan, D; Smith, V; Sverdlov, DY, 2016) |
| "Azelnidipine treatment reduced the pathologic findings normally associated with aneurysm formation within the aortic wall." | 1.39 | Azelnidipine suppresses the progression of aortic aneurysm in wild mice model through anti-inflammatory effects. ( Hirata, Y; Kitagawa, T; Kurobe, H; Matsuoka, Y; Maxfield, MW; Sata, M; Sugasawa, N, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 13 (81.25) | 24.3611 |
| 2020's | 3 (18.75) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, YC | 1 |
| Zhang, XJ | 1 |
| Zhang, JX | 1 |
| Zhai, ZY | 1 |
| Zhang, MX | 1 |
| Jiang, BH | 1 |
| Berman, AG | 2 |
| Romary, DJ | 2 |
| Kerr, KE | 1 |
| Gorazd, NE | 1 |
| Wigand, MM | 1 |
| Patnaik, SS | 1 |
| Finol, EA | 1 |
| Cox, AD | 1 |
| Goergen, CJ | 2 |
| Lian, G | 1 |
| Li, X | 1 |
| Zhang, L | 4 |
| Zhang, Y | 1 |
| Sun, L | 1 |
| Zhang, X | 1 |
| Liu, H | 2 |
| Pang, Y | 1 |
| Kong, W | 1 |
| Zhang, T | 1 |
| Wang, X | 1 |
| Jiang, C | 1 |
| Lv, X | 1 |
| Hu, Y | 1 |
| Chen, X | 2 |
| Chen, L | 1 |
| Lin, Y | 1 |
| Hou, Y | 1 |
| Tang, H | 1 |
| Leung, L | 1 |
| Saturno, G | 1 |
| Viros, A | 1 |
| Smith, D | 1 |
| Di Leva, G | 1 |
| Morrison, E | 1 |
| Niculescu-Duvaz, D | 1 |
| Lopes, F | 1 |
| Johnson, L | 1 |
| Dhomen, N | 1 |
| Springer, C | 1 |
| Marais, R | 1 |
| Zheng, X | 1 |
| Yang, X | 1 |
| Shao, Y | 1 |
| Zhang, S | 1 |
| Lai, H | 1 |
| Zhao, X | 1 |
| Qin, Y | 1 |
| Ding, Y | 1 |
| Chen, R | 1 |
| Li, G | 1 |
| Labrie, M | 1 |
| Ding, Z | 1 |
| Zhou, J | 1 |
| Hu, J | 1 |
| Ma, D | 1 |
| Fang, Y | 1 |
| Gao, Q | 1 |
| Cullen, JM | 1 |
| Lu, G | 2 |
| Shannon, AH | 1 |
| Su, G | 2 |
| Sharma, A | 1 |
| Salmon, M | 1 |
| Fashandi, AZ | 1 |
| Spinosa, MD | 1 |
| Montgomery, WG | 1 |
| Johnston, WF | 1 |
| Ailawadi, G | 2 |
| Upchurch, GR | 2 |
| Li, JS | 1 |
| Li, HY | 1 |
| Wang, L | 2 |
| Jing, ZP | 2 |
| Kurobe, H | 1 |
| Matsuoka, Y | 1 |
| Hirata, Y | 1 |
| Sugasawa, N | 1 |
| Maxfield, MW | 1 |
| Sata, M | 1 |
| Kitagawa, T | 1 |
| Liu, SB | 1 |
| Ikenaga, N | 1 |
| Peng, ZW | 1 |
| Sverdlov, DY | 1 |
| Greenstein, A | 1 |
| Smith, V | 1 |
| Schuppan, D | 1 |
| Popov, Y | 1 |
| Davis, JP | 1 |
| Schaheen, B | 1 |
| Downs, E | 1 |
| Roy, RJ | 1 |
| Budatha, M | 1 |
| Roshanravan, S | 1 |
| Zheng, Q | 1 |
| Weislander, C | 1 |
| Chapman, SL | 1 |
| Davis, EC | 1 |
| Starcher, B | 1 |
| Word, RA | 1 |
| Yanagisawa, H | 1 |
| Schlötzer-Schrehardt, U | 1 |
| Hammer, CM | 1 |
| Krysta, AW | 1 |
| Hofmann-Rummelt, C | 1 |
| Pasutto, F | 1 |
| Sasaki, T | 1 |
| Kruse, FE | 1 |
| Zenkel, M | 1 |
| Pei, YF | 1 |
| Liao, MF | 1 |
| Lu, QS | 1 |
| Zhuang, YF | 1 |
| Zhang, SM | 1 |
16 other studies available for aminopropionitrile and Disease Exacerbation
| Article | Year |
|---|---|
Progression and Regression of Abdominal Aortic Aneurysms in Mice.
Topics: Aminopropionitrile; Animals; Aortic Aneurysm, Abdominal; Collagen; Disease Models, Animal; Disease P | 2021 |
Experimental aortic aneurysm severity and growth depend on topical elastase concentration and lysyl oxidase inhibition.
Topics: Administration, Topical; Aminopropionitrile; Animals; Aorta, Abdominal; Aortic Aneurysm, Abdominal; | 2022 |
High-frequency murine ultrasound provides enhanced metrics of BAPN-induced AAA growth.
Topics: Aminopropionitrile; Animals; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Biomechanical Phenomena; | 2019 |
Macrophage metabolic reprogramming aggravates aortic dissection through the HIF1α-ADAM17 pathway
Topics: Acriflavine; ADAM17 Protein; Aminopropionitrile; Angiotensin II; Animals; Aortic Dissection; Disease | 2019 |
Establishment and effect evaluation of an aortic dissection model induced by different doses of β-aminopropionitrile in rats.
Topics: Aminopropionitrile; Angiotensin II; Animals; Aorta, Thoracic; Aortic Aneurysm, Thoracic; Aortic Diss | 2021 |
Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface.
Topics: Aminopropionitrile; Animals; Biosensing Techniques; Cell Line, Tumor; Cell Membrane; Cell Proliferat | 2017 |
Bilateral superior cervical ganglionectomy attenuates the progression of β-aminopropionitrile-induced aortic dissection in rats.
Topics: Aminopropionitrile; Animals; Aorta; Aortic Dissection; Arterial Pressure; Disease Models, Animal; Di | 2018 |
FAK-ERK activation in cell/matrix adhesion induced by the loss of apolipoprotein E stimulates the malignant progression of ovarian cancer.
Topics: Aminopropionitrile; Animals; Apolipoproteins E; Cell Adhesion; Cell Line, Tumor; Cell Transformation | 2018 |
A novel swine model of abdominal aortic aneurysm.
Topics: Aminopropionitrile; Angioplasty, Balloon; Animals; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Col | 2019 |
Comparison of β-aminopropionitrile-induced aortic dissection model in rats by different administration and dosage.
Topics: Aminopropionitrile; Animals; Aorta, Thoracic; Aortic Aneurysm, Thoracic; Aortic Dissection; Aortic R | 2013 |
Azelnidipine suppresses the progression of aortic aneurysm in wild mice model through anti-inflammatory effects.
Topics: Aminopropionitrile; Angiotensin II; Animals; Anti-Inflammatory Agents; Aorta, Abdominal; Aorta, Thor | 2013 |
Lysyl oxidase activity contributes to collagen stabilization during liver fibrosis progression and limits spontaneous fibrosis reversal in mice.
Topics: Aminopropionitrile; Animals; Carbon Tetrachloride; Collagen; Collagen Type I; Collagen Type I, alpha | 2016 |
A novel chronic advanced stage abdominal aortic aneurysm murine model.
Topics: Aminopropionitrile; Animals; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Aortic Rupture; Chronic D | 2017 |
Extracellular matrix proteases contribute to progression of pelvic organ prolapse in mice and humans.
Topics: Aminopropionitrile; Animals; Cross-Linking Reagents; Disease Progression; Extracellular Matrix; Extr | 2011 |
LOXL1 deficiency in the lamina cribrosa as candidate susceptibility factor for a pseudoexfoliation-specific risk of glaucoma.
Topics: Aged; Aged, 80 and over; Amino Acid Oxidoreductases; Aminopropionitrile; Astrocytes; Cells, Cultured | 2012 |
Dramatic decrease of aortic longitudinal elastic strength in a rat model of aortic dissection.
Topics: Aminopropionitrile; Animals; Aorta, Thoracic; Aortic Aneurysm, Thoracic; Aortic Dissection; Aortic R | 2012 |